董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Hemsley | 男 | Chair and Chief Executive Officer | 73 | 85.62万美元 | 125.11 | 2026-03-02 |
| Valerie Montgomery Rice | 女 | Director | 64 | 42.43万美元 | 0.63 | 2026-03-02 |
| John H. Noseworthy | 男 | Director | 74 | 39.08万美元 | 0.58 | 2026-03-02 |
| F. William McNabb III | 男 | Director | 68 | 39.36万美元 | 1.37 | 2026-03-02 |
| Kristen Gil | 女 | Director | 54 | 51.48万美元 | 0.17 | 2026-03-02 |
| Scott Gottlieb | 男 | Director | 53 | 未披露 | 未持股 | 2026-03-02 |
| Michele J. Hooper | 女 | Director | 74 | 44.13万美元 | 4.00 | 2026-03-02 |
| Timothy P. Flynn | 男 | Director | 69 | 40.08万美元 | 1.36 | 2026-03-02 |
| Paul R. Garcia | 男 | Director | 73 | 36.66万美元 | 0.47 | 2026-03-02 |
| Charles D. Baker | 男 | Director | 69 | 36.61万美元 | 0.10 | 2026-03-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Hemsley | 男 | Chair and Chief Executive Officer | 73 | 85.62万美元 | 125.11 | 2026-03-02 |
| Timothy Noel | 男 | Chief Executive Officer, UnitedHealthcare | 54 | 未披露 | 未持股 | 2026-03-02 |
| Patrick Conway | 男 | Chief Executive Officer, Optum | 51 | 未披露 | 未持股 | 2026-03-02 |
| Wayne DeVeydt | 男 | Chief Financial Officer | 56 | 未披露 | 未持股 | 2026-03-02 |
| Thomas Roos | 男 | Chief Financial Officer of Optum Insight and Senior Vice President | 53 | 未披露 | 未持股 | 2026-03-02 |
| Erin McSweeney | 女 | Chief People Officer and Executive Vice President | 61 | 626.84万美元 | 1.12 | 2026-03-02 |
| Christopher Zaetta | 男 | Chief Legal Officer and Corporate Secretary and Executive Vice President | 54 | 687.33万美元 | 1.03 | 2026-03-02 |
| Dennis Stankiewicz | 男 | Corporate Controller and Chief Accounting Officer | 48 | 未披露 | 未持股 | 2026-03-02 |
董事简历
中英对照 | 中文 | 英文- Stephen Hemsley
-
Stephen Hemsley，自2006年11月起担任联合健康集团的总裁兼首席执行官；自2000年2月起，担任董事会成员。
Stephen Hemsley has served as Chief Financial Officer of UnitedHealth Group since September 2025. Prior to joining UnitedHealth Group, Wayne was Managing Director of Bain Capital, a private investment firm, from March 2022 to Augt 2025. Wayne previoly served as Chief Executive Officer, from January 2018 to January 2020, and Executive Chairman of the Board of Directors, from January 2020 to Augt 2025, of Surgery Partners, an operator of surgical facilities and ancillary services, and Executive Vice President and Chief Financial Officer of Elevance Health (formerly known as Anthem), a health benefits and insurance provider, from 2007 to June 2016. - Stephen Hemsley，自2006年11月起担任联合健康集团的总裁兼首席执行官；自2000年2月起，担任董事会成员。
- Stephen Hemsley has served as Chief Financial Officer of UnitedHealth Group since September 2025. Prior to joining UnitedHealth Group, Wayne was Managing Director of Bain Capital, a private investment firm, from March 2022 to Augt 2025. Wayne previoly served as Chief Executive Officer, from January 2018 to January 2020, and Executive Chairman of the Board of Directors, from January 2020 to Augt 2025, of Surgery Partners, an operator of surgical facilities and ancillary services, and Executive Vice President and Chief Financial Officer of Elevance Health (formerly known as Anthem), a health benefits and insurance provider, from 2007 to June 2016.
- Valerie Montgomery Rice
-
Valerie Montgomery Rice是乔治亚州亚特兰大市莫尔豪斯医学院（Morehouse School of Medicine）的校长兼院长，自2014年起担任这一职务。2011年至2014年，她还担任Morehouse医学院的执行副院长和院长。Morehouse医学院是美国领先的初级保健医生教育机构之一，最近被公认为美国医学院社会责任最高的机构任务。在加入Morehouse医学院之前，她曾于2006年3月至2009年6月担任Meharry医学院院长和卫生事务高级副院长，并担任妇女健康研究中心主任，2005年至2011年，Montgomery Rice博士是美国最早致力于研究对有色人种妇女影响不成比例的疾病的研究中心之一。此前，她还是国家卫生研究所和国家转化科学促进中心的理事会成员，并曾在美国国家卫生研究院少数民族健康与健康差距研究室和妇女健康咨询委员会、美国医学院协会院长理事会等行政委员会任职。Montgomery Rice博士是美国国家医学院院士，著名的不孕症专家和妇女健康研究人员。
Valerie Montgomery Rice,is President and Chief Executive Officer of the Morehouse School of Medicine, a medical school in Atlanta, Georgia. She has been President since 2014 and Chief Executive Officer since 2021. She was Dean of the Morehouse School of Medicine from 2011 to 2021 and Executive Vice President from 2011 to 2014. She was Dean of the School of Medicine and Senior Vice President of Health Affairs at Meharry Medical College from March 2006 to June 2009, and director of the Center for Women's Health Research from 2005 to 2011. Valerie also served previously as a Council Member of the National Institute of Health and National Center for Advancing Translational Science, and on the National Institute of Health's Minority Health and Health Disparities and Office of Research on Women's Health advisory councils, and the Association of American Medical Colleges Council of Deans administrative board. Valerie is a member of the National Academy of Medicine and a renowned infertility specialist and women's health researcher. In the past five years, Valerie also served as a director of 23andMe Holding Co. - Valerie Montgomery Rice是乔治亚州亚特兰大市莫尔豪斯医学院（Morehouse School of Medicine）的校长兼院长，自2014年起担任这一职务。2011年至2014年，她还担任Morehouse医学院的执行副院长和院长。Morehouse医学院是美国领先的初级保健医生教育机构之一，最近被公认为美国医学院社会责任最高的机构任务。在加入Morehouse医学院之前，她曾于2006年3月至2009年6月担任Meharry医学院院长和卫生事务高级副院长，并担任妇女健康研究中心主任，2005年至2011年，Montgomery Rice博士是美国最早致力于研究对有色人种妇女影响不成比例的疾病的研究中心之一。此前，她还是国家卫生研究所和国家转化科学促进中心的理事会成员，并曾在美国国家卫生研究院少数民族健康与健康差距研究室和妇女健康咨询委员会、美国医学院协会院长理事会等行政委员会任职。Montgomery Rice博士是美国国家医学院院士，著名的不孕症专家和妇女健康研究人员。
- Valerie Montgomery Rice,is President and Chief Executive Officer of the Morehouse School of Medicine, a medical school in Atlanta, Georgia. She has been President since 2014 and Chief Executive Officer since 2021. She was Dean of the Morehouse School of Medicine from 2011 to 2021 and Executive Vice President from 2011 to 2014. She was Dean of the School of Medicine and Senior Vice President of Health Affairs at Meharry Medical College from March 2006 to June 2009, and director of the Center for Women's Health Research from 2005 to 2011. Valerie also served previously as a Council Member of the National Institute of Health and National Center for Advancing Translational Science, and on the National Institute of Health's Minority Health and Health Disparities and Office of Research on Women's Health advisory councils, and the Association of American Medical Colleges Council of Deans administrative board. Valerie is a member of the National Academy of Medicine and a renowned infertility specialist and women's health researcher. In the past five years, Valerie also served as a director of 23andMe Holding Co.
- John H. Noseworthy
-
John H. Noseworthy是世界著名的非营利医疗保健组织梅奥诊所的前首席执行官和总裁。他在梅奥诊所工作了28年，于2018年底退休。梅奥诊所被《美国新闻与世界报道》评为美国顶级严重复杂问题患者护理机构荣誉榜上的最佳人选。梅奥诊所照顾来自世界各地143个国家的病人。诺斯沃西博士于1990年加入梅奥诊所，担任各种职务，包括梅奥诊所内部理事会主席、董事会成员、1992年至今，梅奥诊所医学与科学学院神经病学教授、梅奥神经病学系主任，罗切斯特梅奥诊所执行委员会发展部医学主任兼副主席。2007年至2009年，诺西沃西博士还担任美国神经病学学会官方期刊《神经病学》主编。2012年至2018年，诺西沃西博士担任世界经济论坛卫生总监，过去五年，他还担任默克公司董事。
John H. Noseworthy,was the former Chief Executive Officer and President of Mayo Clinic until his retirement in December 2018. John joined Mayo Clinic in 1990 and served in various capacities, including as Chairman of Mayo Clinic's internal Board of Governors, member of the Board of Trustees, Professor of Neurology at Mayo Clinic College of Medicine & Science, Chair of Mayo's Department of Neurology, medical director of the Department of Development and Vice Chair of the Mayo Clinic Rochester Executive Board. John also served as editor-in-chief of Neurology, the official journal of the American Academy of Neurology. He was a Health Governor of the World Economic Forum and, in the past five years, served as a director of Merck & Co. - John H. Noseworthy是世界著名的非营利医疗保健组织梅奥诊所的前首席执行官和总裁。他在梅奥诊所工作了28年，于2018年底退休。梅奥诊所被《美国新闻与世界报道》评为美国顶级严重复杂问题患者护理机构荣誉榜上的最佳人选。梅奥诊所照顾来自世界各地143个国家的病人。诺斯沃西博士于1990年加入梅奥诊所，担任各种职务，包括梅奥诊所内部理事会主席、董事会成员、1992年至今，梅奥诊所医学与科学学院神经病学教授、梅奥神经病学系主任，罗切斯特梅奥诊所执行委员会发展部医学主任兼副主席。2007年至2009年，诺西沃西博士还担任美国神经病学学会官方期刊《神经病学》主编。2012年至2018年，诺西沃西博士担任世界经济论坛卫生总监，过去五年，他还担任默克公司董事。
- John H. Noseworthy,was the former Chief Executive Officer and President of Mayo Clinic until his retirement in December 2018. John joined Mayo Clinic in 1990 and served in various capacities, including as Chairman of Mayo Clinic's internal Board of Governors, member of the Board of Trustees, Professor of Neurology at Mayo Clinic College of Medicine & Science, Chair of Mayo's Department of Neurology, medical director of the Department of Development and Vice Chair of the Mayo Clinic Rochester Executive Board. John also served as editor-in-chief of Neurology, the official journal of the American Academy of Neurology. He was a Health Governor of the World Economic Forum and, in the past five years, served as a director of Merck & Co.
- F. William McNabb III
-
F. William McNabb III从2008年一直担任The Vanguard Group，Inc.的董事长，直到2018年退休。从2008年至2017年，他担任首席执行官。他于1986年加入Vanguard。2010年，他成为董事会主席，先锋投资公司集团的董事会。在职业生涯早期，McNabb先生领导着Vanguard面对业务部门的每个客户。 McNabb先生曾担任投资公司协会理事会副主席，并于2013年至2016年担任董事长。他是UnitedHealth Group的董事，也是其审计委员会的成员。他还是Duff＆Phelps和Axiom的董事。麦克纳布先生是费城动物学会主席，也是安永会计师事务所独立审计质量委员会主席。 McNabb先生还担任过沃顿商学院领导力咨询委员会，达特茅斯体育咨询委员会，哥伦比亚大学艾拉·米尔斯坦全球市场与公司所有权中心咨询委员会的委员，也是CECP的董事会成员。
F. William McNabb III served as chairman of The Vanguard Group, Inc. from 2008 until his retirement in 2018 and served as chief executive officer from 2008 to 2017. He joined Vanguard in 1986. In 2010, he became chairman of the board of directors and the board of trtees of the Vanguard group of investment companies. Earlier in his career, Mr. McNabb led each of Vanguard's client facing biness divisions. Mr. McNabb served as the vice chairman of the Investment Company Institute's Board of Governors and served as its chairman from 2013 to 2016. He is a director of UnitedHealth Group and serves as the chair of its audit committee. He is also a director of Axiom. Mr. McNabb is the former chairman of the board of the Zoological Society of Philadelphia, chairman of the Rowing Foundation, and former chairman of Ernst & Young's Independent Audit Quality Committee. Mr. McNabb also serves on the Wharton Leadership Advisory Board, the Advisory Board of the Ira M. Millstein Center for Global Markets and Corporate Ownership at Columbia University and is also a board member of CECP: The CEO Force for Good. - F. William McNabb III从2008年一直担任The Vanguard Group，Inc.的董事长，直到2018年退休。从2008年至2017年，他担任首席执行官。他于1986年加入Vanguard。2010年，他成为董事会主席，先锋投资公司集团的董事会。在职业生涯早期，McNabb先生领导着Vanguard面对业务部门的每个客户。 McNabb先生曾担任投资公司协会理事会副主席，并于2013年至2016年担任董事长。他是UnitedHealth Group的董事，也是其审计委员会的成员。他还是Duff＆Phelps和Axiom的董事。麦克纳布先生是费城动物学会主席，也是安永会计师事务所独立审计质量委员会主席。 McNabb先生还担任过沃顿商学院领导力咨询委员会，达特茅斯体育咨询委员会，哥伦比亚大学艾拉·米尔斯坦全球市场与公司所有权中心咨询委员会的委员，也是CECP的董事会成员。
- F. William McNabb III served as chairman of The Vanguard Group, Inc. from 2008 until his retirement in 2018 and served as chief executive officer from 2008 to 2017. He joined Vanguard in 1986. In 2010, he became chairman of the board of directors and the board of trtees of the Vanguard group of investment companies. Earlier in his career, Mr. McNabb led each of Vanguard's client facing biness divisions. Mr. McNabb served as the vice chairman of the Investment Company Institute's Board of Governors and served as its chairman from 2013 to 2016. He is a director of UnitedHealth Group and serves as the chair of its audit committee. He is also a director of Axiom. Mr. McNabb is the former chairman of the board of the Zoological Society of Philadelphia, chairman of the Rowing Foundation, and former chairman of Ernst & Young's Independent Audit Quality Committee. Mr. McNabb also serves on the Wharton Leadership Advisory Board, the Advisory Board of the Ira M. Millstein Center for Global Markets and Corporate Ownership at Columbia University and is also a board member of CECP: The CEO Force for Good.
- Kristen Gil
-
Kristen Gil，目前担任Alphabet, Inc.的副总裁兼商业财务官。自2007年加入Alphabet以来，她曾担任多个高级职位，包括b谷歌搜索、地图、研究与人工智能以及可持续发展的业务运营、战略和财务。在2007年加入Alphabet之前，Kristen曾在Marketron International和McKinsey & Company工作。Kristen曾担任网络安全公司Proofpoint的董事会成员。
Kristen Gil,served as Vice President, Business Finance Officer at Alphabet, Inc. until January 2024. She held numerous senior positions at Alphabet since joining the company in 2007, including in business operations, strategy, and finance for Google Search, Maps, Research & AI, and Sustainability. Prior to joining Alphabet in 2007, Kristen worked at Marketron International and McKinsey & Company. In the past five years, Kristen also served as a director of Proofpoint, a cybersecurity company. - Kristen Gil，目前担任Alphabet, Inc.的副总裁兼商业财务官。自2007年加入Alphabet以来，她曾担任多个高级职位，包括b谷歌搜索、地图、研究与人工智能以及可持续发展的业务运营、战略和财务。在2007年加入Alphabet之前，Kristen曾在Marketron International和McKinsey & Company工作。Kristen曾担任网络安全公司Proofpoint的董事会成员。
- Kristen Gil,served as Vice President, Business Finance Officer at Alphabet, Inc. until January 2024. She held numerous senior positions at Alphabet since joining the company in 2007, including in business operations, strategy, and finance for Google Search, Maps, Research & AI, and Sustainability. Prior to joining Alphabet in 2007, Kristen worked at Marketron International and McKinsey & Company. In the past five years, Kristen also served as a director of Proofpoint, a cybersecurity company.
- Scott Gottlieb
-
Scott Gottlieb，他自2009年1月起担任New Enterprise Associates，Inc.董事，从2019年起为美国企业研究所的常驻研究员。也是在纽约大学医学院的医学临床助理教授。从2005年到2007年，曾在美国食品和药物管理局“FDA”担任副处长，负责医学和科学事务。在此之前，从2003年到2004年担任FDA局长的医疗技术高级顾问和医疗FDA政策发展的董事。于2004年春离开了美国FDA，去完成新的医疗保险药物报销的工作，作为医疗保险和医疗补助服务中心的高级顾问，支持运用相关新的医疗技术，提高质量和覆盖范围和支付决策机构的政策工作。目前担任Molecular Insight Pharmaceuticals的董事。国家医学院院士，财经新闻网CNBC撰稿人，是Sinai School of Medicine和Connecticut Wesleyan University的毕业生。
Scott Gottlieb,has been a director since February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. He was elected Chairman of the Board of Directors in March 2025. He is currently a Special Partner at the venture capital firm New Enterprise Associates and a Resident Fellow at the American Enterprise Institute for Public Policy Research, and he serves as a director of Pfizer, Aetion, Tempus Labs, National Resilience and the Mount Sinai Medical System. Dr. Gottlieb held several roles in the public and private sectors prior to serving as FDA Commissioner, including serving as a venture partner at New Enterprise Associates from 2007 to 2017. Dr. Gottlieb was previously the FDA's Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as a senior advisor to the FDA Commissioner from 2003 to 2004. He was also a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. Dr. Gottlieb has advised the states of Massachusetts, Maryland, and Montana on the Covid response as a member of state advisory boards. He is a contributor to CNBC and CBS Face the Nation.Dr. Gottlieb received a B.A. in economics from Wesleyan University and his M.D. from the Icahn School of Medicine at Mount Sinai. - Scott Gottlieb，他自2009年1月起担任New Enterprise Associates，Inc.董事，从2019年起为美国企业研究所的常驻研究员。也是在纽约大学医学院的医学临床助理教授。从2005年到2007年，曾在美国食品和药物管理局“FDA”担任副处长，负责医学和科学事务。在此之前，从2003年到2004年担任FDA局长的医疗技术高级顾问和医疗FDA政策发展的董事。于2004年春离开了美国FDA，去完成新的医疗保险药物报销的工作，作为医疗保险和医疗补助服务中心的高级顾问，支持运用相关新的医疗技术，提高质量和覆盖范围和支付决策机构的政策工作。目前担任Molecular Insight Pharmaceuticals的董事。国家医学院院士，财经新闻网CNBC撰稿人，是Sinai School of Medicine和Connecticut Wesleyan University的毕业生。
- Scott Gottlieb,has been a director since February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. He was elected Chairman of the Board of Directors in March 2025. He is currently a Special Partner at the venture capital firm New Enterprise Associates and a Resident Fellow at the American Enterprise Institute for Public Policy Research, and he serves as a director of Pfizer, Aetion, Tempus Labs, National Resilience and the Mount Sinai Medical System. Dr. Gottlieb held several roles in the public and private sectors prior to serving as FDA Commissioner, including serving as a venture partner at New Enterprise Associates from 2007 to 2017. Dr. Gottlieb was previously the FDA's Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as a senior advisor to the FDA Commissioner from 2003 to 2004. He was also a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. Dr. Gottlieb has advised the states of Massachusetts, Maryland, and Montana on the Covid response as a member of state advisory boards. He is a contributor to CNBC and CBS Face the Nation.Dr. Gottlieb received a B.A. in economics from Wesleyan University and his M.D. from the Icahn School of Medicine at Mount Sinai.
- Michele J. Hooper
-
Michele J. Hooper，她是UnitedHealth Group董事会的首席独立董事，自2021年10月起担任该职务。Michele是The Directors’Council的总裁兼首席执行官，这是她于2003年共同创立的一家私人公司，与公司董事会合作，提高独立性、有效性和多样性。从1999年到2000年，她担任Voyager Expanded Learning的总裁兼首席执行官，这是一家为公立学校提供学习计划和教师培训的开发商和供应商。从1998年到1999年被收购，她曾担任Stadtlander Drug Company， Inc.的总裁兼首席执行官，这是一家提供疾病特定药物护理的公司。Michele是全国公认的公司治理专家。在过去的五年中，Michele也是PPG Industries， Inc.的董事。
Michele J. Hooper,is Lead Independent Director of the Board of Directors of UnitedHealth Group and has served in this capacity since October 2021. Michele is President and CEO of The Directors' Council, a private company she co-founded in 2003 that works with corporate boards to increase their independence, effectiveness and diversity. She was President and CEO of Voyager Expanded Learning, a developer and provider of learning programs and teacher training for public schools, from 1999 until 2000. She previously served as President and CEO of Stadtlander Drug Company, Inc., a provider of disease-specific pharmaceutical care, from 1998 until its acquisition in 1999. Michele is a nationally recognized corporate governance expert. In the past five years, Michele also served as a director of PPG Industries, Inc. - Michele J. Hooper，她是UnitedHealth Group董事会的首席独立董事，自2021年10月起担任该职务。Michele是The Directors’Council的总裁兼首席执行官，这是她于2003年共同创立的一家私人公司，与公司董事会合作，提高独立性、有效性和多样性。从1999年到2000年，她担任Voyager Expanded Learning的总裁兼首席执行官，这是一家为公立学校提供学习计划和教师培训的开发商和供应商。从1998年到1999年被收购，她曾担任Stadtlander Drug Company， Inc.的总裁兼首席执行官，这是一家提供疾病特定药物护理的公司。Michele是全国公认的公司治理专家。在过去的五年中，Michele也是PPG Industries， Inc.的董事。
- Michele J. Hooper,is Lead Independent Director of the Board of Directors of UnitedHealth Group and has served in this capacity since October 2021. Michele is President and CEO of The Directors' Council, a private company she co-founded in 2003 that works with corporate boards to increase their independence, effectiveness and diversity. She was President and CEO of Voyager Expanded Learning, a developer and provider of learning programs and teacher training for public schools, from 1999 until 2000. She previously served as President and CEO of Stadtlander Drug Company, Inc., a provider of disease-specific pharmaceutical care, from 1998 until its acquisition in 1999. Michele is a nationally recognized corporate governance expert. In the past five years, Michele also served as a director of PPG Industries, Inc.
- Timothy P. Flynn
-
Timothy P. Flynn，2017年1月加入UnitedHealth Group董事会，自2012年起担任摩根大通 & Co.董事会成员。他在摩根大通 & Co.董事会的任期将于2024年5月结束。Flynn先生还于2016年11月至2021年5月期间在美国铝业公司董事会任职。他此前于2013年9月起担任丘博保险公司的董事会成员，直至2016年1月该公司被收购。他还曾担任财务会计准则委员会受托人、世界经济论坛国际商业理事会成员、国际综合报告理事会理事。Flynn先生毕业于明尼苏达州圣保罗市圣托马斯大学，是该校董事会成员。
Timothy P. Flynn,joined the board of directors of UnitedHealth Group Incorporated in January 2017. He also served on the board of directors of JPMorgan Chase & Co from May 2012 to May 2024 and on the board of directors of Alcoa Corporation from November 2016 until May 2021. He previously served as a member of the board of directors of The Chubb Corporation from September 2013 until its acquisition in January 2016. He also previously served as a trustee of the Financial Accounting Standards Board, a member of the World Economic Forum's International Business Council, and a director of the International Integrated Reporting Council. Mr. Flynn graduated from the University of St. Thomas, St. Paul, Minnesota and is a member of the school's board of trustees. - Timothy P. Flynn，2017年1月加入UnitedHealth Group董事会，自2012年起担任摩根大通 & Co.董事会成员。他在摩根大通 & Co.董事会的任期将于2024年5月结束。Flynn先生还于2016年11月至2021年5月期间在美国铝业公司董事会任职。他此前于2013年9月起担任丘博保险公司的董事会成员，直至2016年1月该公司被收购。他还曾担任财务会计准则委员会受托人、世界经济论坛国际商业理事会成员、国际综合报告理事会理事。Flynn先生毕业于明尼苏达州圣保罗市圣托马斯大学，是该校董事会成员。
- Timothy P. Flynn,joined the board of directors of UnitedHealth Group Incorporated in January 2017. He also served on the board of directors of JPMorgan Chase & Co from May 2012 to May 2024 and on the board of directors of Alcoa Corporation from November 2016 until May 2021. He previously served as a member of the board of directors of The Chubb Corporation from September 2013 until its acquisition in January 2016. He also previously served as a trustee of the Financial Accounting Standards Board, a member of the World Economic Forum's International Business Council, and a director of the International Integrated Reporting Council. Mr. Flynn graduated from the University of St. Thomas, St. Paul, Minnesota and is a member of the school's board of trustees.
- Paul R. Garcia
-
Paul R. Garcia自业务合并以来一直担任董事，Garcia先生于1999年6月至2014年5月担任全球支付公司Global Payments Inc.（NYSE：GPN）的董事长兼首席执行官，该公司是一家领先的信用卡处理、支票授权和其他电子支付处理服务提供商。Garcia先生自2019年12月起担任银行控股公司Truist Financial Corp.（NYSE：TFC）董事以及2014年8月至2019年12月担任SunTrust Banks，Inc.（NYSE：STI）董事。Garcia先生还担任支付联盟国际董事，此前曾在Dun&BradStreet Corporation（2012年5月至2019年2月）、West Corporation（2013年3月至2017年10月）和Global Payments Inc.（2001年2月至2014年5月）的董事会任职。
Paul R. Garcia,is the retired Chairman and Chief Executive Officer of Global Payments Inc., a publicly traded, leading provider of electronic payment processing services, and served in that capacity from 1999 to 2014. Prior to his role at Global Payments, Paul served as President & CEO of NaBanco, an electronic credit card processor, from 1982 to 1995. He served as a director of Global Payments Inc., MasterCard International, West Corporation and The Dun & Bradstreet Corporation and, in the past five years, as a director of Truist Financial Corporation and Payment Alliance International, Inc. - Paul R. Garcia自业务合并以来一直担任董事，Garcia先生于1999年6月至2014年5月担任全球支付公司Global Payments Inc.（NYSE：GPN）的董事长兼首席执行官，该公司是一家领先的信用卡处理、支票授权和其他电子支付处理服务提供商。Garcia先生自2019年12月起担任银行控股公司Truist Financial Corp.（NYSE：TFC）董事以及2014年8月至2019年12月担任SunTrust Banks，Inc.（NYSE：STI）董事。Garcia先生还担任支付联盟国际董事，此前曾在Dun&BradStreet Corporation（2012年5月至2019年2月）、West Corporation（2013年3月至2017年10月）和Global Payments Inc.（2001年2月至2014年5月）的董事会任职。
- Paul R. Garcia,is the retired Chairman and Chief Executive Officer of Global Payments Inc., a publicly traded, leading provider of electronic payment processing services, and served in that capacity from 1999 to 2014. Prior to his role at Global Payments, Paul served as President & CEO of NaBanco, an electronic credit card processor, from 1982 to 1995. He served as a director of Global Payments Inc., MasterCard International, West Corporation and The Dun & Bradstreet Corporation and, in the past five years, as a director of Truist Financial Corporation and Payment Alliance International, Inc.
- Charles D. Baker
-
Charles D. Baker于2012年6月担任董事会成员。Mr. Baker是General Catalyst Partners的创业合伙人，专注于在中型企业的投资，主要是健康护理服务行业。在加入General Catalyst之前，他是马萨诸州州长的候选人。1999年至2009年，Mr. Baker担任Harvard Pilgrim Health Care HPHC的首席执行官，一个市值20亿美元的，为100万个人和员工提供健康福利的计划。在他的任期期间，HPHC连续五年成为国家公民满意度和临床疗效排名最高的健康计划。在九十年代，Mr. Baker担任Health and Human Services的秘书和马萨诸塞州行政管理和财务秘书。他也在几个私人组织的董事会任职。
Charles D. Baker,is President of the National Collegiate Athletic Association, a nonprofit organization dedicated to the well-being and success of college athletes, and has served in that role since March 1, 2023. He was the Governor of the Commonwealth of Massachusetts from January 8, 2015 to January 2, 2023. Prior to his tenure as Governor, Charlie had a distinguished career in business, non-profit, and government administration. Immediately preceding his role as Governor, he served as Executive in Residence at General Catalyst Partners, where he served as an advisor to a variety of companies. Earlier in his career, Charlie also served as CEO of Harvard Pilgrim Health Care, a health benefits provider. - Charles D. Baker于2012年6月担任董事会成员。Mr. Baker是General Catalyst Partners的创业合伙人，专注于在中型企业的投资，主要是健康护理服务行业。在加入General Catalyst之前，他是马萨诸州州长的候选人。1999年至2009年，Mr. Baker担任Harvard Pilgrim Health Care HPHC的首席执行官，一个市值20亿美元的，为100万个人和员工提供健康福利的计划。在他的任期期间，HPHC连续五年成为国家公民满意度和临床疗效排名最高的健康计划。在九十年代，Mr. Baker担任Health and Human Services的秘书和马萨诸塞州行政管理和财务秘书。他也在几个私人组织的董事会任职。
- Charles D. Baker,is President of the National Collegiate Athletic Association, a nonprofit organization dedicated to the well-being and success of college athletes, and has served in that role since March 1, 2023. He was the Governor of the Commonwealth of Massachusetts from January 8, 2015 to January 2, 2023. Prior to his tenure as Governor, Charlie had a distinguished career in business, non-profit, and government administration. Immediately preceding his role as Governor, he served as Executive in Residence at General Catalyst Partners, where he served as an advisor to a variety of companies. Earlier in his career, Charlie also served as CEO of Harvard Pilgrim Health Care, a health benefits provider.
高管简历
中英对照 | 中文 | 英文- Stephen Hemsley
Stephen Hemsley，自2006年11月起担任联合健康集团的总裁兼首席执行官；自2000年2月起，担任董事会成员。
Stephen Hemsley has served as Chief Financial Officer of UnitedHealth Group since September 2025. Prior to joining UnitedHealth Group, Wayne was Managing Director of Bain Capital, a private investment firm, from March 2022 to Augt 2025. Wayne previoly served as Chief Executive Officer, from January 2018 to January 2020, and Executive Chairman of the Board of Directors, from January 2020 to Augt 2025, of Surgery Partners, an operator of surgical facilities and ancillary services, and Executive Vice President and Chief Financial Officer of Elevance Health (formerly known as Anthem), a health benefits and insurance provider, from 2007 to June 2016.- Stephen Hemsley，自2006年11月起担任联合健康集团的总裁兼首席执行官；自2000年2月起，担任董事会成员。
- Stephen Hemsley has served as Chief Financial Officer of UnitedHealth Group since September 2025. Prior to joining UnitedHealth Group, Wayne was Managing Director of Bain Capital, a private investment firm, from March 2022 to Augt 2025. Wayne previoly served as Chief Executive Officer, from January 2018 to January 2020, and Executive Chairman of the Board of Directors, from January 2020 to Augt 2025, of Surgery Partners, an operator of surgical facilities and ancillary services, and Executive Vice President and Chief Financial Officer of Elevance Health (formerly known as Anthem), a health benefits and insurance provider, from 2007 to June 2016.
- Timothy Noel
Timothy Noel，自2025年1月起担任UnitedHealthcare的首席执行官。此前，他曾担任UnitedHealth的医疗保险和退休业务的首席执行官，并自2007年加入UnitedHealth Group以来担任多个领导职务，包括担任医疗保险和退休联邦产品的首席财务官和高级副总裁。
Timothy Noel has served as Chief Executive Officer of UnitedHealthcare since January 2025. Previoly, Tim served as Chief Executive Officer of UnitedHealthcare's Medicare & Retirement biness and held numero leadership roles since joining UnitedHealth Group from 2007 until January 2025, including serving as Chief Financial Officer and Senior Vice President of federal products for Medicare & Retirement.- Timothy Noel，自2025年1月起担任UnitedHealthcare的首席执行官。此前，他曾担任UnitedHealth的医疗保险和退休业务的首席执行官，并自2007年加入UnitedHealth Group以来担任多个领导职务，包括担任医疗保险和退休联邦产品的首席财务官和高级副总裁。
- Timothy Noel has served as Chief Executive Officer of UnitedHealthcare since January 2025. Previoly, Tim served as Chief Executive Officer of UnitedHealthcare's Medicare & Retirement biness and held numero leadership roles since joining UnitedHealth Group from 2007 until January 2025, including serving as Chief Financial Officer and Senior Vice President of federal products for Medicare & Retirement.
- Patrick Conway
Patrick Conway自2025年5月起担任Optum首席执行官。Previoly，Patrick自2020年2月加入联合健康以来，担任Optum RX的首席执行官并担任数字领导职务，包括担任Optum Health Care Solutions的首席执行官。在加入联合健康之前，Patrick在私营和公共部门以及临床环境中担任过重要的高级领导职务，包括在医疗保险和医疗补助服务中心担任首席医疗官和代理管理员，并担任CMS创新中心主任。
Patrick Conway has served as Chief Executive Officer of Optum since May 2025. Previoly, Patrick served as Optum Rx's Chief Executive Officer and held numero leadership roles since joining UnitedHealth Group in February 2020, including service as Chief Executive Officer of Optum Health Care Solutions. Prior to joining UnitedHealth Group, Patrick held prominent senior leadership positions in the private and public sector and clinical settings, including service as Chief Medical Officer and acting administrator at Centers for Medicare and Medicaid Services, and as director of the CMS Innovation Center.- Patrick Conway自2025年5月起担任Optum首席执行官。Previoly，Patrick自2020年2月加入联合健康以来，担任Optum RX的首席执行官并担任数字领导职务，包括担任Optum Health Care Solutions的首席执行官。在加入联合健康之前，Patrick在私营和公共部门以及临床环境中担任过重要的高级领导职务，包括在医疗保险和医疗补助服务中心担任首席医疗官和代理管理员，并担任CMS创新中心主任。
- Patrick Conway has served as Chief Executive Officer of Optum since May 2025. Previoly, Patrick served as Optum Rx's Chief Executive Officer and held numero leadership roles since joining UnitedHealth Group in February 2020, including service as Chief Executive Officer of Optum Health Care Solutions. Prior to joining UnitedHealth Group, Patrick held prominent senior leadership positions in the private and public sector and clinical settings, including service as Chief Medical Officer and acting administrator at Centers for Medicare and Medicaid Services, and as director of the CMS Innovation Center.
- Wayne DeVeydt
Wayne DeVeydt自2020年1月起担任医疗保健服务公司Surgery Partners, Inc.的董事会执行主席。在此之前，他于2018年1月至2020年1月担任Surgery Partners的首席执行官兼董事会成员。在加盟Surgery Partners, Inc.之前，他曾于2017年1月至2018年1月在全球多元资产另类资产公司Bain Capital资本全球医疗保健部门担任高级顾问，于2007年5月在健康保险公司Anthem, Inc.担任执行副总裁兼CFO，Anthem, Inc.是Blue Cross and Blue Shield Association的独立持牌人，至2016年6月退休。他还于2005年开始担任Anthem公司高级副总裁兼首席会计干事，并于2006年至2007年担任董事长兼首席执行官的办公室主任。在加入Anthem, Inc.之前，DeVeydt先生于1996年至2005年期间担任普华永道会计师事务所的合伙人，在金融服务行业担任过许多职务。DeVeydt先生是Surgery Partners, Inc.的董事会成员，目前担任Surgery Partners, Inc.的执行主席。2016年12月至2019年12月，他担任Grupo Notre Dame Intermedica董事会成员，并担任审计委员会主席。2016年至2018年7月，他还担任Myovant Sciences董事，并担任公司首席独立董事、审计委员会主席、薪酬委员会成员。DeVeydt先生通过他的慈善活动在他的社区中是一个积极的领导者。
Wayne DeVeydt has served as Chief Financial Officer of UnitedHealth Group since September 2025. Prior to joining UnitedHealth Group, Wayne was Managing Director of Bain Capital, a private investment firm, from March 2022 to Augt 2025. Wayne previoly served as Chief Executive Officer, from January 2018 to January 2020, and Executive Chairman of the Board of Directors, from January 2020 to Augt 2025, of Surgery Partners, an operator of surgical facilities and ancillary services, and Executive Vice President and Chief Financial Officer of Elevance Health (formerly known as Anthem), a health benefits and insurance provider, from 2007 to June 2016.- Wayne DeVeydt自2020年1月起担任医疗保健服务公司Surgery Partners, Inc.的董事会执行主席。在此之前，他于2018年1月至2020年1月担任Surgery Partners的首席执行官兼董事会成员。在加盟Surgery Partners, Inc.之前，他曾于2017年1月至2018年1月在全球多元资产另类资产公司Bain Capital资本全球医疗保健部门担任高级顾问，于2007年5月在健康保险公司Anthem, Inc.担任执行副总裁兼CFO，Anthem, Inc.是Blue Cross and Blue Shield Association的独立持牌人，至2016年6月退休。他还于2005年开始担任Anthem公司高级副总裁兼首席会计干事，并于2006年至2007年担任董事长兼首席执行官的办公室主任。在加入Anthem, Inc.之前，DeVeydt先生于1996年至2005年期间担任普华永道会计师事务所的合伙人，在金融服务行业担任过许多职务。DeVeydt先生是Surgery Partners, Inc.的董事会成员，目前担任Surgery Partners, Inc.的执行主席。2016年12月至2019年12月，他担任Grupo Notre Dame Intermedica董事会成员，并担任审计委员会主席。2016年至2018年7月，他还担任Myovant Sciences董事，并担任公司首席独立董事、审计委员会主席、薪酬委员会成员。DeVeydt先生通过他的慈善活动在他的社区中是一个积极的领导者。
- Wayne DeVeydt has served as Chief Financial Officer of UnitedHealth Group since September 2025. Prior to joining UnitedHealth Group, Wayne was Managing Director of Bain Capital, a private investment firm, from March 2022 to Augt 2025. Wayne previoly served as Chief Executive Officer, from January 2018 to January 2020, and Executive Chairman of the Board of Directors, from January 2020 to Augt 2025, of Surgery Partners, an operator of surgical facilities and ancillary services, and Executive Vice President and Chief Financial Officer of Elevance Health (formerly known as Anthem), a health benefits and insurance provider, from 2007 to June 2016.
- Thomas Roos
Thomas Roos，他是UnitedHealth Group的高级副总裁兼首席会计官（2015年8月以来）。加入UnitedHealth Group公司之前，他曾担任Deloitte & Touche公司（一个独立的注册会计师事务所）的合伙人（从2007年9月到2015年8月）。
Thomas Roos has served as Senior Vice President and Chief Accounting Officer of UnitedHealth Group since Augt 2015. Prior to joining UnitedHealth Group, Tom was a Partner at Deloitte & Touche LLP, an independent registered public accounting firm.- Thomas Roos，他是UnitedHealth Group的高级副总裁兼首席会计官（2015年8月以来）。加入UnitedHealth Group公司之前，他曾担任Deloitte & Touche公司（一个独立的注册会计师事务所）的合伙人（从2007年9月到2015年8月）。
- Thomas Roos has served as Senior Vice President and Chief Accounting Officer of UnitedHealth Group since Augt 2015. Prior to joining UnitedHealth Group, Tom was a Partner at Deloitte & Touche LLP, an independent registered public accounting firm.
- Erin McSweeney
Erin McSweeney，自2022年3月起担任联合健康执行副总裁兼首席人事官。2021年2月至2022年3月，Erin担任联合健康行政长官办公室的参谋长。2017年1月至2021年2月，她在Optum担任执行副总裁兼首席人力资源官。在加入联合健康之前，Erin是国际科技公司EMC Corporation的执行副总裁兼首席人力资源官。
Erin McSweeney has served as Executive Vice President and Chief People Officer of UnitedHealth Group since March 2022. From February 2021 to March 2022, Erin served as chief of staff to UnitedHealth Group's Office of the Chief Executive. From January 2017 to February 2021, she served as Executive Vice President and Chief Human Resces Officer at Optum. Prior to joining UnitedHealth Group, Erin was Executive Vice President and Chief Human Resces Officer for EMC Corporation, an international technology company.- Erin McSweeney，自2022年3月起担任联合健康执行副总裁兼首席人事官。2021年2月至2022年3月，Erin担任联合健康行政长官办公室的参谋长。2017年1月至2021年2月，她在Optum担任执行副总裁兼首席人力资源官。在加入联合健康之前，Erin是国际科技公司EMC Corporation的执行副总裁兼首席人力资源官。
- Erin McSweeney has served as Executive Vice President and Chief People Officer of UnitedHealth Group since March 2022. From February 2021 to March 2022, Erin served as chief of staff to UnitedHealth Group's Office of the Chief Executive. From January 2017 to February 2021, she served as Executive Vice President and Chief Human Resces Officer at Optum. Prior to joining UnitedHealth Group, Erin was Executive Vice President and Chief Human Resces Officer for EMC Corporation, an international technology company.
- Christopher Zaetta
Christopher Zaetta，自2024年5月起担任UnitedHealth Group的执行副总裁、首席法务官和公司秘书。此前，Chris从2020年9月至2024年5月担任Optum的首席法务官。在2020年加入Optum之前，Chris曾担任制药公司Johnson & Johnson的副总裁。2011年5月至2019年9月，Chris还在UnitedHealth Group担任多个领导职务，包括该组织政府业务的诉讼主管和总法律顾问。
Christopher Zaetta has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of UnitedHealth Group since May 2024. Previoly, Chris served as Chief Legal Officer of Optum from September 2020 until May 2024. Prior to joining Optum in 2020, Chris was Vice President at Johnson & Johnson, a pharmaceutical company. Chris also held several leadership roles at UnitedHealth Group from May 2011 to September 2019, including Head of Litigation and General Counsel of the organization's government binesses.- Christopher Zaetta，自2024年5月起担任UnitedHealth Group的执行副总裁、首席法务官和公司秘书。此前，Chris从2020年9月至2024年5月担任Optum的首席法务官。在2020年加入Optum之前，Chris曾担任制药公司Johnson & Johnson的副总裁。2011年5月至2019年9月，Chris还在UnitedHealth Group担任多个领导职务，包括该组织政府业务的诉讼主管和总法律顾问。
- Christopher Zaetta has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of UnitedHealth Group since May 2024. Previoly, Chris served as Chief Legal Officer of Optum from September 2020 until May 2024. Prior to joining Optum in 2020, Chris was Vice President at Johnson & Johnson, a pharmaceutical company. Chris also held several leadership roles at UnitedHealth Group from May 2011 to September 2019, including Head of Litigation and General Counsel of the organization's government binesses.
- Dennis Stankiewicz
Dennis Stankiewicz，2016年8月加入公司，担任总审计师。在加入公司之前，Stankiewicz先生是Deloitte & Touche，LLP的合伙人，拥有超过24年的专业经验。
Dennis Stankiewicz joined the Company in Augt 2016 and served as its General Auditor. Prior to joining the Company, Mr. Stankiewicz was a partner with Deloitte & Touche, LLP and has more than 24 years of professional experience.- Dennis Stankiewicz，2016年8月加入公司，担任总审计师。在加入公司之前，Stankiewicz先生是Deloitte & Touche，LLP的合伙人，拥有超过24年的专业经验。
- Dennis Stankiewicz joined the Company in Augt 2016 and served as its General Auditor. Prior to joining the Company, Mr. Stankiewicz was a partner with Deloitte & Touche, LLP and has more than 24 years of professional experience.